A recent IQVIA Institute report forecasts that spending on cancer medicines is expected to reach $375Bn globally by 2027, up from $196Bn in 2022. As companies seek to bring these therapies to market and investors make decisions about what to fund, this discussion will provide insights from clinical stage companies and investors along with regulatory considerations on how to contribute to better outcomes for patients.